We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-10.62%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.76B
AUM Growth
-$25.9M
Cap. Flow
+$293M
Cap. Flow %
10.61%
Top 10 Hldgs %
58.38%
Holding
114
New
31
Increased
18
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
C icon
Citigroup
C
+$14.9M
2
DG icon
Dollar General
DG
+$14.5M
3
MJN
Mead Johnson Nutrition Company
MJN
+$12.2M
4
APTV icon
Aptiv
APTV
+$9.58M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.21M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$11.8M
2
GS icon
Goldman Sachs
GS
+$8.41M
3
CCI icon
Crown Castle
CCI
+$7.34M
4
XOMA
Xoma
XOMA
+$7.26M
5
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$5.55M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 22.6%
2 Healthcare 22.12%
3 Consumer Staples 1.28%
4 Financials 0.7%
5 Real Estate 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$591M 21.38%
28,749,089
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$438M 15.87%
36,196,019
– –
SPY icon
3
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$131M 4.74%
700,000
– –
C icon
4
CALL
Citigroup
C
$222B
$88.1M 3.19%
1,850,000
+1,550,000
+517% +$77.2M
MRK icon
5
CALL
Merck
MRK
$326B
$73.8M 2.67%
1,362,400
-209,600
-13% -$10.9M
IBB icon
6
CALL
iShares Biotechnology ETF
IBB
$9.55B
$70.9M 2.57%
+900,000
New +$75M
FURX
7
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$69.5M 2.52%
798,900
-71,942
-8% -$5.55M
AMZN icon
8
CALL
Amazon
AMZN
$2.48T
$50.5M 1.83%
+3,000,000
New +$55.7M
GOOG icon
9
CALL
Alphabet (Google) Class C
GOOG
$4.07T
$50.2M 1.82%
1,806,747
+1,003,748
+125% +$29.2M
PEP icon
10
CALL
PepsiCo
PEP
$195B
$50.1M 1.81%
600,000
+300,000
+100% +$24.4M
YUM icon
11
CALL
Yum! Brands
YUM
$41.4B
$45.2M 1.64%
834,600
+278,200
+50% +$14.7M
QCOM icon
12
CALL
Qualcomm
QCOM
$172B
$43.4M 1.57%
550,000
– –
GM icon
13
CALL
General Motors
GM
$81.7B
$43M 1.56%
1,250,000
+950,000
+317% +$34.9M
AIG icon
14
CALL
American International
AIG
$42.9B
$42.5M 1.54%
850,000
+250,000
+42% +$12.4M
GE icon
15
CALL
GE Aerospace
GE
$377B
$38.8M 1.41%
312,993
-104,331
-25% -$12.9M
AUXL
16
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$37.4M 1.35%
1,375,000
-125,000
-8% -$3.32M
CIT
17
CALL
DELISTED
CIT Group Inc.
CIT
$36.8M 1.33%
+750,000
New +$36.5M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$12B
$35.8M 1.3%
525,000
+125,000
+31% +$9.21M
TEVA icon
19
CALL
Teva Pharmaceuticals
TEVA
$36.9B
$31.7M 1.15%
600,000
-100,000
-14% -$4.62M
BRFS
20
CALL
DELISTED
BRF SA
BRFS
$30M 1.08%
1,500,000
+1,000,000
+200% +$18.3M
MET icon
21
CALL
MetLife
MET
$62.7B
$26.4M 0.96%
+561,000
New +$25.8M
BMY icon
22
CALL
Bristol-Myers Squibb
BMY
$130B
$26M 0.94%
+500,000
New +$26.6M
WFC icon
23
CALL
Wells Fargo
WFC
$263B
$24.9M 0.9%
500,000
-750,000
-60% -$34.9M
AUXL
24
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$24.5M 0.89%
900,000
-300,000
-25% -$7.96M
BIIB icon
25
CALL
Biogen
BIIB
$30.4B
$22.9M 0.83%
+75,000
New +$23.8M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2014 Portfolio in Review

As of Q1 2014, Artal Group held 114 positions worth $2.76B, down 0.93% from $2.79B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group deployed $293M of net new capital in Q1 2014, opening 31 new positions and adding to 18 existing holdings. Its largest new stake was Citigroup: 300,000 shares worth $14.3M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 23% of assets, down from 35% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was Acorda Therapeutics, an estimated $11.8M trimmed.

  • Artal Group's largest Q1 2014 buy was Citigroup: 300,000 shares worth $14.3M.
  • Artal Group added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $9.21M increase.
  • Artal Group's biggest Q1 2014 reduction was Acorda Therapeutics, cutting an estimated $11.8M.
  • Artal Group fully exited Goldman Sachs in Q1 2014, selling an estimated $8.41M.
  • Artal Group's ten largest holdings make up 58% of its $2.76B portfolio in Q1 2014.
  • Artal Group opened 31 new positions and closed 20 in Q1 2014.
  • Artal Group's portfolio value fell 0.93% quarter-over-quarter to $2.76B.

Based on Artal Group's 13F filing for Q1 2014, filed 15 May 2014.